- The report discusses a multi-factor model suitable for the constituents of the CSI 300 Index, combined with a small-cap high-growth portfolio as an external satellite strategy to improve the performance of the CSI 300 enhanced strategy[1][3][5] - The internal part of the enhanced strategy uses a multi-factor model based on fundamental and momentum indicators, including factors such as ROE, ROE YoY, SUE, expected net profit adjustment, accelerated growth, cash flow ratio, value (dividend yield and BP equal weight composite), momentum, buy-in strength after opening, and large order-driven rise[16][17] - The external part of the enhanced strategy uses a small-cap high-growth portfolio, constructed using factors such as SUE, EAV, expected net profit adjustment, cumulative R&D investment, PB_INT, small-cap, late trading volume ratio, and large order net buy-in ratio after opening[35][36] - The internal multi-factor model shows more stable stock selection performance within the CSI 300 Index constituents compared to the all-A multi-factor model, with higher IC and RankIC information ratios[16][17] - The small-cap high-growth portfolio has an annualized return of 25.0% since 2016, with an annualized excess return of 24.4% relative to the CSI 300 Index, but also higher tracking error[35][36] - The GARP strategy, which balances growth potential and reasonable pricing, is also considered as an external satellite strategy, showing an annualized return of 20.9% for the GARP 20 portfolio and 17.4% for the GARP 50 portfolio since 2016[39][40][42] - Combining the internal multi-factor model and external satellite strategies (small-cap high-growth or GARP) can significantly improve the performance of the CSI 300 enhanced strategy, with annualized excess returns not less than 10% and information ratios above 2.0 since 2016[29][45][55] Model and Factor Construction Process - **Internal Multi-Factor Model**: Constructed using fundamental and momentum indicators, including ROE, ROE YoY, SUE, expected net profit adjustment, accelerated growth, cash flow ratio, value (dividend yield and BP equal weight composite), momentum, buy-in strength after opening, and large order-driven rise[16][17] - **Small-Cap High-Growth Portfolio**: Constructed using factors such as SUE, EAV, expected net profit adjustment, cumulative R&D investment, PB_INT, small-cap, late trading volume ratio, and large order net buy-in ratio after opening[35][36] - **GARP Strategy**: Constructed by excluding high-risk stocks, using PB and dividend yield as value factors, and ROE, SUE, EAV, expected net profit adjustment, and two-year compound growth rate as growth factors, selecting the top 20 or 50 stocks based on composite scores[41][42] Model and Factor Performance Metrics - **Internal Multi-Factor Model**: IC monthly average 6.36%, IC monthly win rate 67.0%, annualized ICIR 1.67; RankIC monthly average 7.53%, RankIC monthly win rate 72.2%, annualized ICIR 2.00[17] - **Small-Cap High-Growth Portfolio**: Annualized return 25.0%, annualized excess return 24.4%, tracking error 20.3%, information ratio 1.21, relative drawdown 39.6%, monthly win rate 61.4%[36] - **GARP 20 Portfolio**: Annualized return 20.9%, annualized excess return 20.3%, tracking error 15.8%, information ratio 1.26, relative drawdown 36.0%[42] - **GARP 50 Portfolio**: Annualized return 17.4%, annualized excess return 16.8%, tracking error 14.6%, information ratio 1.14, relative drawdown 37.2%[42] Combined Strategy Performance - **Internal 20% + External 10% (Small-Cap High-Growth)**: Annualized excess return 11.7%, information ratio 2.35, tracking error 5.2%, relative drawdown 21.9%[45][48] - **Internal 20% + External 10% (GARP)**: Annualized excess return 11.3%, information ratio 2.41, tracking error 4.3%, relative drawdown 5.8%[50][53]

Investment Rating - The report rates the military industry as "Overweight" [5] Core Views - The military industry is expected to perform well in the long term due to increasing great power competition and rising defense expenditures [9][20] - Recent developments include the joint naval exercises between China and Russia, and the U.S. building a counter-drone defense system [8][20] - The report highlights the restructuring of China's aviation supply chain and the importance of domestic production capabilities in the aerospace sector [22][23] Summary by Sections Investment Highlights - Recommended stocks include: 1) Assembly: AVIC Shenyang Aircraft (600760.SH), AVIC Xi'an Aircraft (000768.SZ), AVIC South Lake (688552.SH) 2) Components: AVIC Optoelectronics (002179.SZ), Guobang Electronics (603678.SH), Ruichuang Micro-Nano (688002.SH) 3) Subsystems: AVIC Aircraft (600372.SH), North Navigation (600435.SH) 4) Materials and Processing: Feilihua (300395.SZ), Guangwei Composite (300699.SZ), Huayin Technology (688281.SH) [5][9][10] Market Performance - The defense military index rose by 5.24% from August 4 to August 8, outperforming the Shanghai Composite Index by 3.13 percentage points [11][12] - The military industry ranked 3rd out of 29 sectors during this period [12] Major News in the Military Industry - The joint naval exercises "Maritime Joint-2025" between China and Russia included real combat training and operational coordination [20][21] - The U.S. is developing a counter-drone defense system, with Ukraine being a testing ground for various technologies [8][9] - Japan is expanding its military influence through participation in multinational exercises, indicating a shift in its defense posture [28][30]

Investment Rating - The investment rating for the company is "Accumulate" [3][17]. Core Views - The company demonstrates steady revenue growth, balancing product expansion and brand promotion, with significant R&D advantages expected to lead to innovative products in gynecology, hair care, and serious medical fields [1]. - The company has established a mature branding strategy and is building a global system for its products, with multiple patents approved in various regions [9]. Financial Summary - Total revenue is projected to grow from 780 million in 2023 to 3,534 million by 2027, reflecting a compound annual growth rate (CAGR) of 28.2% [2][10]. - Net profit attributable to the parent company is expected to increase from 300 million in 2023 to 1,814 million in 2027, with a CAGR of 29.4% [2][10]. - Earnings per share (EPS) is forecasted to rise from 2.61 yuan in 2023 to 15.77 yuan in 2027 [2][10]. - The return on equity (ROE) is projected to remain strong, starting at 31.4% in 2023 and declining to 34.2% by 2027 [2][10]. Market Data - The target price for the company's stock is set at 402.74 yuan [3]. - The stock has a 52-week price range of 151.90 to 577.50 yuan [4]. - The total market capitalization is approximately 34.86 billion yuan [4]. Business Segments - The medical device segment reported revenue of 708 million in the first half of 2025, a year-on-year increase of 33.41% [9]. - The functional skincare segment saw a significant revenue increase of 152.39%, reaching 121 million in the same period [9]. - The raw materials segment experienced a modest growth of 12.40%, with revenue of 27 million [9]. Operational Highlights - The company has successfully obtained patents for its collagen products in Brazil and FDA certifications for several skincare products in the U.S. [9]. - Marketing strategies include collaborations with leading medical institutions and participation in academic summits and international expos to enhance brand recognition [9].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price set at 94.48 CNY [2][12]. Core Insights - The company has exceeded performance expectations in the first half of 2025, driven by its deep focus on 3D vision technology and the introduction of multiple new products. The acceleration of robotics and 3D printing applications is expected to lead to rapid revenue growth [3][12]. - The company reported a revenue of 4.35 billion CNY in H1 2025, representing a year-on-year increase of 104.14%, and achieved a net profit of 0.60 billion CNY, marking a turnaround from losses [12]. - The report highlights the company's advancements in 3D vision solutions for various robotics applications, including service robots and industrial robots, and the launch of new products such as the Pulsar ME450 and Gemini 345Lg [12]. Financial Summary - Revenue projections show significant growth from 360 million CNY in 2023 to 1.94 billion CNY in 2027, with a compound annual growth rate (CAGR) of 67.9% from 2024 to 2025 [5][13]. - The net profit is expected to turn positive by 2025, reaching 134 million CNY, and further increasing to 608 million CNY by 2027 [5][13]. - The earnings per share (EPS) is projected to improve from -0.69 CNY in 2023 to 1.52 CNY in 2027 [5][13]. Market Data - The company's stock has shown a 52-week price range of 21.53 to 85.47 CNY, with a total market capitalization of 32.08 billion CNY [6]. - The stock has experienced a significant absolute increase of 235% over the past 12 months [10]. Product Development and Market Trends - The company is focusing on enhancing its product matrix in the 3D vision sector, with applications in 3D printing and digital twin technologies. The global demand for 3D scanners is projected to grow from 4.9 billion USD in 2024 to 8.8 billion USD by 2030 [12]. - The report emphasizes the potential for growth driven by the increasing adoption of humanoid robots and the rapid penetration of 3D printing technologies [12].

Investment Rating - The investment rating for China Unicom is "Accumulate" with a target price of 7.59 CNY [6][12]. Core Insights - The company continues to optimize its cost structure and enhance operational efficiency, with a focus on R&D investments in AI and computing power, laying a solid foundation for high-quality development [2]. - In the first half of 2025, the company achieved steady revenue growth, with total operating income reaching 200.2 billion CNY (YoY +1.5%) and net profit attributable to shareholders at 6.349 billion CNY (YoY +5.1%) [12]. - The intelligent computing business has become a core growth engine, contributing 45.4 billion CNY in revenue, accounting for 26% of total operating income [12]. - The company has effectively controlled capital expenditures, which decreased by 15% year-on-year, while increasing R&D expenses by 15.6% to 3.46 billion CNY [12]. Financial Summary - Total operating revenue is projected to grow from 372.6 billion CNY in 2023 to 439.4 billion CNY in 2027, with a CAGR of approximately 4.9% [5]. - Net profit attributable to shareholders is expected to increase from 8.17 billion CNY in 2023 to 11.24 billion CNY in 2027, reflecting a CAGR of about 9.2% [5]. - The earnings per share (EPS) is forecasted to rise from 0.26 CNY in 2023 to 0.36 CNY in 2027 [5]. - The return on equity (ROE) is anticipated to improve from 5.1% in 2023 to 6.2% in 2027 [5]. Business Performance - The intelligent computing business has shown strong momentum, with cloud revenue reaching 37.6 billion CNY and data center revenue growing by 9.4% to 14.4 billion CNY [12]. - The connectivity business remains stable, with revenue of 131.9 billion CNY and a user base exceeding 480 million, marking a net increase of over 11 million users in the first half of 2025 [12]. - The company has maintained a stable average revenue per user (ARPU) while achieving high-quality user growth [12].

Investment Rating - The report assigns an "Overweight" rating for the industry, indicating an expected performance that exceeds the Shanghai and Shenzhen 300 Index by more than 15% [4][11]. Core Insights - The implementation of the "Personal Consumption Loan Interest Subsidy Policy" is expected to enhance consumer demand and improve the consumption finance and insurance sectors. The subsidy reflects a downward trend in interest rates, which may be lower than anticipated [2][4]. Summary by Sections Policy Overview - The policy aims to stimulate consumption and expand domestic demand by providing interest subsidies for eligible personal consumption loans. The subsidy is set at 1 percentage point and applies to key consumption areas such as household vehicles and general consumption below 50,000 yuan [4]. Implementation Details - The policy will be effective from September 1, 2025, to August 31, 2026. It covers two categories of consumption: general consumption below 50,000 yuan and key consumption of 50,000 yuan and above, with a maximum subsidy of 3,000 yuan per individual [4]. Impact on Financial Institutions - The subsidy is expected to stimulate demand for consumer credit, benefiting consumer finance companies directly. It will lower borrowing costs for consumers, potentially leading to an expansion in the scale of consumer loans and an increase in business volume and revenue for consumer finance institutions [4]. Recommendations - The report recommends investing in leading companies in the automotive finance sector, such as Yixin Group, which is well-positioned to benefit from the policy's support for household vehicle consumption. Additionally, it suggests insurance sector stocks like New China Life Insurance and China Life Insurance due to improved interest rate expectations [4][5].

Market Performance - The A-share market showed overall recovery from August 4 to August 8, 2025, with the CSI 300 index rising by 1.23%, the ESG 300 index increasing by 1.06%, and the STAR Market ESG index up by 1.31%[5] - The average daily trading volume across the A-share market was approximately 1.70 trillion RMB, indicating a contraction in liquidity compared to previous periods[5] ESG Fund Issuance - No new ESG fund products were issued in August 2025; however, a total of 241 ESG public funds were launched in the past year, with a total issuance of 171.41 billion units[7] - As of August 10, 2025, there are 910 existing ESG fund products, with the largest share being ESG strategy funds at 50.33% of the total net asset value of 1,022.06 billion RMB[9] Fund Performance - The top-performing fund for the week of August 4 to August 10, 2025, was the Zhonghai Charm Yangtze River fund, achieving a weekly return of 6.14% and a year-to-date return of 29.00%[10] - Other notable funds included the Robeco Resource Selection and Yongying New Energy Selection, which also performed well during the same period[10] Green Bond Issuance - A total of 23 new green bonds were issued in the interbank and exchange markets from August 4 to August 8, 2025, with a planned issuance scale of approximately 18.64 billion RMB[13] - In August 2025, 33 ESG bonds were issued, amounting to 15.3 billion RMB, with a total of 1,034 ESG bonds issued in the past year, totaling 1,227.7 billion RMB[13] Green Bond Trading - The total trading volume of ESG green bonds for the week was 562.58 billion RMB, with the interbank market accounting for 77.45% of the total trading volume[17] - Repo transactions dominated the trading methods, comprising 94.96% of the total trading volume, while cash transactions accounted for only 0.07%[20] Bank Wealth Management Products - In August 2025, 30 ESG bank wealth management products were issued, with a total of 1,049 existing products in the market as of August 10, 2025[18] - The largest share of existing products is pure ESG-themed products, which account for 54.53% of the total[18] Risk Factors - Potential risks include insufficient policy support for ESG initiatives, lack of standardized data reporting, and lower-than-expected product issuance scales[19]

Market Overview - The cumulative trading volume of carbon emission allowances in the national carbon market increased to 3.2428 million tons, with a transaction amount of 225.8395 million yuan, reflecting an increase of 30.17% and 23.92% respectively compared to the previous week[18] - The average daily transaction price of carbon emission allowances (CEA) was 69.59 yuan/ton, down by 4.85% from the previous week[18] International Carbon Market Trends - In the European market, EUA spot prices rose by 3.36% to 72.56 euros/ton, while trading volume decreased by 55.17% to 104,000 tons[6] - The EUA futures price increased by 3.35% to 73.22 euros/ton, with a slight decrease in trading volume of 0.07% to 2.87 million tons[6] - In the US market, EUA futures prices rose by 3.33% to 73.21 euros/ton, with trading volume increasing by 0.75% to 136.29 million tons[9] Domestic Market Insights - The trading volume in domestic pilot carbon markets decreased by 64.00% to 211,700 tons, with major trading concentrated in Shenzhen, Shanghai, Hubei, and Guangdong, accounting for 97.47% of total trading volume[24] - The average transaction price in Guangdong's carbon market dropped by 4.53%, marking the largest decline among pilot markets[22] Policy Developments - The People's Bank of China and six other departments issued guidelines to support new industrialization, focusing on enhancing technological innovation and supply chain resilience[25] - Shanghai's new policy for market-oriented pricing of renewable energy will ensure that all new energy projects will participate in market trading by the end of 2025, promoting a sustainable energy system[28] Risk Factors - Economic recovery may not meet expectations, and there are risks associated with unexpected policy relaxations and climate anomalies[29]

- The Black-Litterman model (BL model) is used for asset allocation, combining investor views with market equilibrium[17][20] - The construction process of the BL model involves adjusting the expected returns based on investor views and then optimizing the portfolio using mean-variance optimization[17][20] - The Risk Parity model aims to allocate risk equally across all assets in a portfolio, rather than allocating capital equally[27][30] - The construction process of the Risk Parity model involves calculating the risk contribution of each asset and solving an optimization problem to equalize these contributions[28][29][30] - The Counter-Cyclical Allocation model adjusts asset allocation based on economic cycles, aiming to reduce risk during downturns and increase exposure during upturns[11][43] - The Macro Momentum Timing model uses macroeconomic indicators to time market entries and exits, aiming to capture trends and avoid downturns[11][60] - The Sentiment Timing model uses investor sentiment indicators to time market entries and exits, aiming to capitalize on market overreactions[67] Model Performance Metrics - **Black-Litterman Model**: Annualized return 6.58%, maximum drawdown 3.18%, annualized volatility 2.15%, Sharpe ratio 1.86, Calmar ratio 2.07[22][24] - **Risk Parity Model**: Annualized return 6.07%, maximum drawdown 3.78%, annualized volatility 2.26%, Sharpe ratio 1.58, Calmar ratio 1.61[31] - **Counter-Cyclical Allocation Model**: Annualized return 7.36%, maximum drawdown 8.85%, annualized volatility 6.12%, Sharpe ratio 1.13, Calmar ratio 0.85[43][47] - **Macro Momentum Timing Model**: Annualized return 7.06%, maximum drawdown 6.60%, annualized volatility 6.06%, Sharpe ratio 1.13, Calmar ratio 1.97[60] - **Sentiment Timing Model**: Annualized return 7.74%, maximum drawdown 24.91%, annualized volatility 17.49%, Sharpe ratio 1.01, Calmar ratio 0.62[67][87]

Investment Rating - The report assigns an "Accumulate" rating to the company, with a target price of HKD 29.19 [5][15]. Core Insights - The report highlights that the company focuses on high-quality fat reduction and muscle gain in weight loss, as well as unmet needs in oncology, indicating a globally competitive pipeline in these areas [2][10]. - The company is positioned as a science-driven, clinical-stage biopharmaceutical firm, aiming to provide innovative therapies for metabolic diseases, cancer, and liver fibrosis [20][19]. Financial Summary - The projected financials for the company indicate no revenue until 2025, with expected revenues of RMB 280 million in 2027. The net profit is forecasted to be negative in the coming years, with estimates of -RMB 369 million in 2023, improving to -RMB 190 million by 2027 [4][15]. - The company’s financial ratios show a significant increase in the price-to-book (PB) ratio from 9.66 in 2024 to 429.89 in 2027, reflecting the anticipated growth in valuation as the company progresses [4][11]. Pipeline and Market Focus - The company’s pipeline includes several clinical trials targeting obesity and cancer, with a focus on LAE102, LAE002 (afuresertib), and LAE001, which are positioned to address unmet medical needs in these therapeutic areas [23][24]. - The report emphasizes the growing global market for weight loss drugs, projected to exceed USD 115 billion by 2030, driven by increasing obesity rates and demand for effective treatments [34][32]. Management and Team Experience - The management team possesses extensive experience in the pharmaceutical industry, with key members having backgrounds in leading global pharmaceutical companies, which enhances the company’s capability in drug development and clinical trials [30][25]. Competitive Landscape - The report notes that the company is innovating in the "fat reduction + muscle gain" space, which is becoming a critical focus in the weight loss drug market, with several multinational corporations also investing in this area [45][48].